

CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 1,279,125,560 NEW ORDINARY SHARES IN THE CAPITAL OF CLEARBRIDGE HEALTH LIMITED (“PROPOSED RIGHTS ISSUE”)

- RECEIPT OF LISTING AND QUOTATION NOTICE

1. Introduction

1.1 The board of directors (the “**Board**” or “**Directors**”) of Clearbridge Health Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the Company’s announcements dated 27 September 2024, 7 October 2024, 16 October 2024 and 23 October 2024 (the “**Previous Announcements**”) in relation to the Proposed Rights Issue. Shareholders have approved, amongst others, the Proposed Rights Issue at the extraordinary general meeting of the Company held on 23 October 2024.

1.2 Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meaning ascribed to them in the Previous Announcements.

2. Receipt of Listing and Quotation Notice

2.1 The Board is pleased to announce that the Company has on 25 October 2024 received the listing and quotation notice from the SGX-ST for the dealing in, listing of and quotation for, up to 1,279,125,560 Rights Shares on the Catalist Board of the SGX-ST (the “**LQN**”). The LQN is subject to the Company’s compliance with the SGX-ST’s listing requirements.

2.2 The LQN is not to be taken as an indication of the merits of the Proposed Rights Issue, the Rights Shares, the Company, its subsidiaries and their securities.

3. Cautionary Statement

Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares. As at the date of this announcement, there is no certainty or assurance that the Proposed Rights Issue will be completed or that no changes will be made to the terms thereof. The Company will make the necessary announcements when there are further developments. Shareholders and potential investors are advised to read this announcement, the Previous Announcements and any further announcements by the Company carefully. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

28 October 2024

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "Sponsor"), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalyst.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms. Goh Mei Xian, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.